Session » Osteoarthritis & Joint Biology – Basic Science Poster (1468–1479)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1478

An Orphan Receptor and Osteoarthritis: Mouse Gpr34 Expression in Dorsal Root Ganglia After Partial Meniscectomy

8:30AM-10:30AM: Abstract Number: 1474

Automatic Detection of Bone Marrow Lesions from Knee MRI Data from the OAI Study

8:30AM-10:30AM: Abstract Number: 1470

Cartilage Epigenetic Changes Induced by Microbial DNA Amplified from Human OA Samples

8:30AM-10:30AM: Abstract Number: 1479

CD14, a Toll-like Receptor Co-Factor, Influences Osteoclast Differentiation and Activity, but Does Not Alter Osteoblastic Potential of Bone-Marrow Precursors in Mice

8:30AM-10:30AM: Abstract Number: 1473

Chaperone-mediated Autophagy Is a Hallmark of Joint Damage in Osteoarthritic Patients

8:30AM-10:30AM: Abstract Number: 1472

Characterization and Function of Tumor Necrosis Factor α and Interleukin-6–Induced Osteoclasts in Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 1477

Circulating MicroRNAs in Hand Osteoarthritis

8:30AM-10:30AM: Abstract Number: 1468

Intra-articular (IA) Injection of Empty Large Multilamellar Vesicles Liposomes Reduces Cartilage Degeneration in Rat Osteoarthritis Model

8:30AM-10:30AM: Abstract Number: 1475

Long Term Compressive Loading Modulates the Extracellular Matrix Response to Growth Factors in Bovine Cartilage Explants

8:30AM-10:30AM: Abstract Number: 1469

Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries

8:30AM-10:30AM: Abstract Number: 1476

Metabolic Reprogramming: Inhibiting Osteoarthritis-induced Expression of the Pyruvate Dehydrogenase Kinase Preserves Mitochondrial Respiration

8:30AM-10:30AM: Abstract Number: 1471

Oral Administration of Berberine Limits Post-traumatic Osteoarthritis Development and Associated Pain via AMP-activated Protein Kinase (AMPK) in Mice

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].